Form PTO-1449 (Modified) U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 28967/35061A	Serial No. 09/427,657
INFORMATION DISCLOSURE STATEMENT	Applicant Alitalo et al.	
	Filing Date 10/26/99	Group 1636

U.S. PATENT DOCUMENTS

		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	A26	6,107,046	08-22-2000	Alitalo et al.	435	7.1	7/28/97
	A27	6,130,071	10-10-2000	Alitalo et al.	435	69.4	2/5/97
	A28	6,221,839	04-24-2001	Alitalo et al.	512	12	8/11/95
	A29	6,235,713	05-22-2001	Achen et al.	514	12	8/21/97
	A30	6,245,530	06-12-2001	Alitalo et al.	435	6934	1/12/96
	A31	6,361,946	03-26-2002	Alitalo et al.	435	6	2/2/98
	A32	6,403,088	06-11-2002	Alitalo	424	139.1	2/14/96
	A33	6,451,764	09-17-2002	Lee et al.	514	12	8/30/96
	A34	6,576,608	06-10-2003	Lee et al.	514	2	5/17/99
	A35	6,645,933	11-11-2003	Alitalo et al.	514	2	6/28/96
	A36	2002/0123481	09-05-2002	Oliviero, S.			05-07-2002
	A37	2002/0127222	09-12-2002	Achen et al.			12-23-1998
	A38	2003/0091567	05-15-2003	Alitalo et al.			07-23-2002
	A39	2003/0092604	05-15-2003	Alitalo et al.			07-23-2002
	A40	2003/0166547	09-04-2003	Oliviero, S.			06-19-2002
	A41	2003/0166873	09-04-2003	Lee et al.			01-17-2003
	A42	2003/0180294	09-25-2003	DeVries, G.			02-22-2002
	A43	2004/0037820	02-26-2004	Alitalo et al.			01-19-2001

FOREIGN PATENT DOCUMENTS

*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation Yes	Translation No
	B16	EP 0935001	08-11-1999	EPO				
	~~B17~~	~~WO 98/02543~~	~~01-22-1998~~	~~PCT~~				X

EXAMINER	DATE CONSIDERED 11/15/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 28967/35061A	Serial No. 09/427,657
		Applicant Alitalo et al.	
		Filing Date Oct 26, 1999	Group ~~1633~~ 1636

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
ED	A1	5,087,244	02/11/92	Wolinsky *et al.*	604	33	9/27/90
	A2	5,631,237	05/20/97	Dzau *et al.*	514	44	5/10/94
	A3	5,653,689	08/05/97	Buelna *et al.*	604	96	9/30/95
	A4	5,674,192	10/07/97	Sahatjian *et al.*	604	28	7/23/93
	A5	5,679,400	10/21/97	Tuch	427	2.14	6/7/95
	A6	5,697,967	12/16/97	Dinh *et al.*	623	1	4/27/95
	A7	5,700,286	12/23/97	Tartaglia *et al.*	623	1	8/22/96
	A8	5,707,385	01/13/98	Williams *et al.*	606	192	11/16/94
	A9	5,713,860	02/03/98	Kaplan *et al.*	604	96	11/13/95
	A10	5,749,848	05/12/98	Jang *et al.*	604	53	10/9/96
	A11	5,776,184	07/07/98	Tuch	623	1	11/14/94
	A12	5,776,755	07/07/98	Alitalo *et al.*	435	194	2/8/96
	A13	5,779,729	07/14/98	Severini	606	191	5/15/96
	A14	5,785,965	07/28/98	Pratt *et al.*	424	93.21	6/7/95
	A15	5,792,453	08/11/98	Hammond *et al.*	424	93.21	6/7/95
	A16	5,795,898	08/18/98	Brown *et al.*	514	263	10/23/96
	A17	5,799,384	09/01/98	Schwartz *et al.*	29	458	10/23/96
	A18	5,800,507	09/01/98	Schwartz *et al.*	623	1	4/27/95
	A19	5,824,048	10/20/98	Tuch	623	1	10/9/96
	A20	5,830,879	11/03/98	Isner *et al.*	514	44	10/2/95

> DUPLICATE w/o attached

EXAMINER	DATE CONSIDERED 10-14-01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 28967/35061A	Serial No. 09/427,657
INFORMATION DISCLOSURE STATEMENT *(Use several sheets if necessary)*		Applicant Alitalo et al.	
		Filing Date Oct 26, 1999	Group 1633

U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
KS	A21	5,924,048	07/13/99	McCormack *et al.*	702	13	3/14/97
	A22	5,932,540	08/03/99	Hu *et al.*	514	2	12/24/97
	A23	5,935,820	08/10/99	Hu *et al.*	435	69.4	3/27/97
	A24	5,994,300	11/30/99	Bayne, *et al.*	514	12	11/20/93
	A25	6,040,157	03/21/00	Hu *et al.*	435	69.4	3/13/98

FOREIGN PATENT DOCUMENTS

*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation Yes	Translation No
KS	B1	95/24473	09/14/95	WO				
	B2	96/24473	09/14/95	WO				
	B3	96/39515	12/12/96	WO				
	B4	97/05250	02/13/97	WO				
	B5	97/09427	03/13/97	WO				
	B6	97/17359	05/15/97	WO				
	B7	97/17442	05/15/97	WO				
	B8	98/07832	02/26/98	WO				
	B9	98/19712	05/14/98	WO				
	B10	98/20027	05/14/98	WO				
	B11	98/24811	06/11/98	WO				
	B12	98/33917	08/06/98	WO				

EXAMINER	DATE CONSIDERED 10-16-01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 28967/35061A	Serial No. 09/427,657
INFORMATION DISCLOSURE STATEMENT *(Use several sheets if necessary)*		Applicant Alitalo et al.	
		Filing Date Oct 26, 1999	Group 1633

FOREIGN PATENT DOCUMENTS

*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation Yes	Translation No
KJ	B13	98/49300	11/05/98	WO				
	B14	99/07844	02/18/99	WO				
	B15	99/46364	09/16/99	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

KJ	C1	Achen, M.G. *et al.*, "Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)," *Proc. Natl. Acad. Sci. USA 95(2)*:548-553 (January, 1998).
	C2	Alitalo *et al.*, "Vascular Endothelial Growth Factors B and C and Receptors Involved in Angiogenesis," *German-American Academic Council Foundation (GAAC)/ Stiftung Deutsch-Amerikanisches Akademisches Konzil (DAAK), 2nd Symposium on Current Problems in Molecular Medicine: The Role of Cytokines in Human Disease*, November 17-20, 1996, Ringberg Castle, Germany, p. 1 (*ABSTRACT*).
	C3	Asahara, *et al.*, "Accelerated restitution of endothelial integrity and endothelium-dependent function after phVEGF$_{165}$ gene transfer," *Circulation 94*:3291-3302 (1996).
	C4	Asahara, *et al.*, "Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery," *Circulation 91*:2793-2801 (1995).
	C5	Barr, *et al.*, "Efficient catheter-mediated gene transfer into the heart using replication-defective adenovirus," *Gene Ther. 1*:51-58 (1994).
	C6	Boshart, *et al.*, "A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus," *Cell 41*:521-530 (June, 1985).
	C7	Callow, *et al.*, "Vascular permeability factor accelerates endothelial regrowth following balloon angioplasty," *Growth Factors 10*:223-228 (1994).

EXAMINER	DATE CONSIDERED 10-16-01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 28967/35061A	Serial No. 09/427,657
INFORMATION DISCLOSURE STATEMENT *(Use several sheets if necessary)*		Applicant Alitalo et al.	
		Filing Date Oct 26, 1999	Group 1633

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
KJ	C8	Camenzind *et al.*, "Use of Locally Delivered Conventional Drug Therapies," *Semin Intervent Cardiol* 1:67-76 (1996).
	C9	Cao, *et al.*, "Vascular endothelial growth factor-C induces angiogenesis *in vivo*," *Proc. Natl. Acad. Sci. 95*:14389-14394 (1998).
	C10	Cerek, *et al.*, "Growth factors in pathogenesis of coronary arterial restenosis," *Am. J. Cardiol.* 68:24C-33C (November, 1991).
	C11	Chang, *et al.*, "Gene therapy for vascular proliferative disorders," *Semin. Intervent. Cardiol. 1*:185-193 (1996).
	C12	Darius, *et al.*, "Lokale Medikamentengabe und Gentherapie," *Herz 22*:347-54 (1997).
	C13	Davis, *et al.*, "Direct gene transfer into skeletal muscle in vivo: factors affecting efficiency of transfer and stability of expression," *Hum. Gene Ther. 4*:151-9 (1993).
	C14	Debbas, *et al.*, "*Stenting within a stent: Treatment for repeat in-stent restenosis* in a venous graft," *American Heart Journal 133*:460-468 (April, 1997).
	C15	De Meyer, et al., "Mechanisms of neointima formation-lessons from experimental models," *Vasc. Med.* 2:179-189 (1997).
	C16	DeYoung, *et al.*, "Gene therapy for restenosis: Are we ready?," *Circ. Res. 82*:306-313 (1998).
	C17	Dignam, *et al.*, "Balbiani ring 3 in Chironomus tentans encodes a 185-kDa secretory protein which is synthesized throughout the fourth larval instar," *Gene 88*:133-140 (1990).
	C18	Enholm, *et al.*, "Vascular endothelial growth factor-C, a growth factor for lymphatic endothelial cells," *Trends in Cardiovascular Med. 8*:292-297 (1998).
	C19	Enholm, *et al.*, "Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia," *Oncogene 14*:2475-2483 (1997).

EXAMINER	DATE CONSIDERED 10-26-01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 28967/35061A	Serial No. 09/427,657
INFORMATION DISCLOSURE STATEMENT *(Use several sheets if necessary)*		Applicant Alitalo et al.	
		Filing Date Oct 26, 1999	Group 1633

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
ES	C20	Feldman, *et al.*, "Perspectives of arterial gene therapy for the prevention of restenosis," *Cardiovascular Research 32*:194-207 (1996).
	C21	Ferrara, *et al.*, "Clinical applications of angiogenic growth factors and their inhibitors," *Nature Med 5*:1359-64 (December 1999).
	C22	GenBank Accession No. AJ000185 Homo sapiens mRNA for vascular endothelial growth factor-D.
	C23	GenBank Accession No. AF014827 Rattus norvegicus vascular endothelial growth factor-D (VEGF-D) mRNA, complete cds.
	C24	GenBank Accession No. MMU73620 Mus musculus VEGF-C mRNA, complete cds.
	C25	GenBank Accession No. CCY15837 Coturnix coturnix mRNA for vascular endothelial growth factor C.
	C26	GenBank Accession No. D89628 Mus musculus mRNA for vascular endothelial growth factor D, complete cds.
	C27	GenBank Accession No. X94216 H. sapiens mRNA for VEGF-C protein.
	C28	Gnatenko, *et al.*, "Characterization of recombinant adeno-associated virus-2 as a vehicle for gene delivery and expression into vascular cells," *J. Investig. Med. 45*:87-89 (1997).
	C29	Grosskreutz, *et al.*, "Vascular endothelial growth-factor-induced migration of vascular smooth muscle cells in vitro," *Microvasc. Res. 58(2)*:128-136 (1999).
	C30	Hu, *et al.*, "A novel regulatory function of proteolytically cleaved VEGF-2 for vascular endothelial and smooth muscle cells," *FASEB J. 11*:498-504 (1997).
	C31	International Search Report for PCT/US99/24054.
	C32	Isner, *et al.*, "Arterial gene therapy for therapeutic angiogenesis in patients with peripheral artery disease," *Circulation 91*:2687-2692 (1995).
	C33	Isner, *et al.*, "Arterial gene therapy for restenosis," *Human Gene Therapy 7*:989-1011 (May, 1996).

EXAMINER	DATE CONSIDERED 10-14-01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 28967/35061A	Serial No. 09/427,657
INFORMATION DISCLOSURE STATEMENT *(Use several sheets if necessary)*		Applicant Alitalo et al.	
		Filing Date Oct 26, 1999	Group 1633

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
	C34	Jeltsch, *et al.*, "Hyperplasia of lymphatic vessels in VEGF-C transgenic mice," *Science 276*:1423-1425 (1997).
	C35	Joukov, *et al.*, "Vascular endothelial growth factors VEGF-B and VEGF-C," *J. Cell Physiol 173*:211-215 (1997).
	C36	Joukov, *et al.*, "Proteolytic processing regulates receptor specificity and activity of VEGF-C," *EMBO J. 16(13)*:3898-3911 (1997).
	C37	Joukov, *et al.*, "A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities," *J. Biol. Chem. 273(12)*:6599-6602 (March, 1998).
	C38	Joukov, *et al.*, "A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases," *EMJO J. 15*:290-298 (1996).
	C39	Jussila, *et al.*, "Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3," *Cancer Res. 58(8)*:1599-604 (1998).
	C40	Kagan, *et al.*, "Mediators of restenosis," *Surgical Clinics of North America 78*:481-500 (June, 1998).
	C41	Kim, *et al.*, "Minimal requirements for lentivirus vector based on human immunodeficiency virus type 1," *J. Virol. 72(1)*:811-816 (January, 1998).
	C42	Kingsman *et al.*, "A new generation of gene therapy vectors," *Scrip Magazine* 43-46 (October, 1998).
	C43	Korhonen, *et al.*, "Endothelial-specific gene expression directed by the tie gene promoter in vivo," *Blood 86(5)*:1828-1835 (September, 1995).
	C44	Kukk, *et al.*, "VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development," *Development 122*:3829-3839 (1996).

EXAMINER	DATE CONSIDERED 10-14-01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 28967/35061A	Serial No. 09/427,657
INFORMATION DISCLOSURE STATEMENT *(Use several sheets if necessary)*		Applicant Alitalo et al.	
		Filing Date Oct 26, 1999	Group 1633

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
	C45	Laitinen, *et al.*, "VEGF gene transfer reduces intimal thickening via increased production of nitric oxide in carotid arteries," *Hum. Gene Ther 8*:1737-1744 (October, 1997).
	C46	Laitinen, *et al.*, "Adenovirus-mediated gene transfer to lower limb artery of patients with chronic critical leg ischemia," *Hum. Gene Ther. 9*:1481-1486 (July, 1998).
	C47	Laitinen, *et al.*, "Adventitial gene transfer to arterial wall," *Pharmacol Res* 37:251-254 (1998).
	C48	Lambert, *et al.*, "Local drug delivery catheters: functional comparison of porous and microporous designs," *Coron. Artery Dis. 4*:469-475 (1993).
	C49	Lee, *et al.*, "Vascular endothelial growth factor-related protein: A ligand and specific activator of the tyrosine kinase receptor Flt4," *Proc. Natl. Acad. Sci. USA 93*:1988-1992 (1996).
	C50	Lehner, *et al.*, "Comparative sequence analysis of human cytomegalovirus strains," *J. Clin. Microbiol. 29*:2494-2502 (November, 1991).
	C51	Libby, "Gene therapy of restenosis: Promise and Perils," *Circ. Res. 82*:404-406 (1998).
	C52	Lincoff, *et al.*, "Local drug delivery for the prevention of restenosis: Fact, Fancy, and Future," *Circulation 90*:2070-2084 (1994).
	C53	Lymboussaki, *et al.*, "Expression of the vascular endothelial growth factor C receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors," *Am J. Path 153*:395-403 (August, 1998).
	C54	Marchió, *et al.*, "Vascular endothelial growth factor-C stimulates the migration and proliferation of Kaposi's sarcoma cells," *J. Biol. Chem. 274*:27617-27622 (September, 1999).
	C55	Mazur, *et al.*, "Coronary restenosis and gene therapy," *Texas Heart Institute Journal 21*:104-111 (1994).

EXAMINER	E Boddell	DATE CONSIDERED	10-24-01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 28967/35061A	Serial No. 09/427,657
INFORMATION DISCLOSURE STATEMENT *(Use several sheets if necessary)*		Applicant Alitalo et al.	
		Filing Date Oct 26, 1999	Group 1633

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
KS	C56	Morishita, *et al.*, "Contribution of a vascular modulator, hepatocyte growth factor (HGF), to the pathogenesis of cardiovascular disease," *J. Atherosclerosis and Thrombosis 4(3)*:128-134 (1998).
	C57	Mulligan, "The basic science of gene therapy," *Science 260*:926-932 (May, 1993).
	C58	Narins, *et al.*, "A call for provisional stenting: The balloon in back," *Circulation 97*:1298-1305 (1998).
	C59	Oh, *et al.*, "VEGF and VEGF-C: Specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane," *Dev. Biol. 188*:96-109 (1997).
	C60	Ohno, *et al.*, "Gene therapy for vascular smooth muscle cell proliferation after arterial injury," *Science 265*:781-784 (August, 1994).
	C61	Paavonen *et al.*, "Chromosomal Localization and Regulation of Human Vascular Endothelial Growth Factors B and C (VEGF-B and VEGF-C)," *IX International Vascular Biology Meeting*, Seattle, Washington, September 4-8, 1996, p. 76 (*ABSTRACT 299*).
	C62	Paavonen *et al.*, "Novel Human Vascular Endothelial Growth Factor Genes VEGF-B and VEGF-C Localize to Chromosomes 11q13 and 4q34, Respectively," *Circulation 93(6)*:1079-1082 (March 15, 1996).
	C63	Paulsson, *et al.*, "The Balbiani ring 3 gene in Chironomus tentans has diverged repetitive structure split by many introns," *J. Mol. Biol. 211*:331-349 (1990).
	C64	Pepper, *et al.*, "Vascular endothelial growth factor (VEGF)-C synergizes with basic fibroblast growth factor and VEGF in the induction of angiogenesis in vitro and alters endothelial cell extracellular proteolytic activity," *J. Cell Physiol.* 177:439-452 (1998).
	C65	Quantin, *et al.*, "Adenovirus as an expression vector in muscle cells in vivo," *Proc. Natl. Acad. Sci. USA 89*:2581-2584 (April, 1992).
	C66	Riessen, *et al.*, "Arterial gene transfer using pure DNA applied directly to a hydrogel-coated angioplasty balloon," *Human Gene Therapy 4*:749-758 (1993).

EXAMINER E Landsman	DATE CONSIDERED 10-14-01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 28967/35061A	Serial No. 09/427,657
INFORMATION DISCLOSURE STATEMENT *(Use several sheets if necessary)*		Applicant Alitalo et al.	
		Filing Date Oct 26, 1999	Group 1633

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
KJ	C67	Riessen, *et al*, "Prospects for site-specific delivery of pharmacologic and molecular therapies," *J. Am. Coll. Cardiol. 23*:1234-1244 (April, 1994).
	C68	Rosenfeld, *et al.*, "In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium," *Cell 68*:143-155 (January, 1992).
	C69	Salven, *et al.*, "Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors," *Am. J. Pathol. 153*:103-108 (1998).
	C70	Sambrook *et al., Molecular Cloning: A Laboratory Manual*, 2nd ed., Cold Spring Harbor Laboratory Press, § 9.47-9.51 (1989).
	C71	Schwartz, "The vessel wall reaction in restenosis," *Semin Intervent Cardiol* 2:83-88 (1997).
	C72	Serruys, *et al.*, "Heparin-coated Palmaz-Schatz stents in human coronary arteries," *Circulation 93*:412-422 (1996).
	C73	Shih, *et al.*, "Focal accumulation of an apolipoprotein B-based synthetic oligopeptide in the healing rabbit arterial wall," *Proc Natl. Acad Sci. USA 87*:1436-1440 (February, 1990).
	C74	Steg, et al., "Arterial gene transfer to the rabbit endothelial and smooth muscle cells using percutaneous delivery of an adenoviral vector," *Circulation 90*:1648-1656 (1994).
	C75	Steg, *et al.*, "Reduction of restenosis after angioplasty in a atheromatous rabbit model by suicide gene therapy," *Circulation 96*:408-411 (1997).
	C76	Stratford-Perricaudet, *et al.*, "Widespread long-term gene transfer to mouse skeletal muscles and heart," *J. Clin. Invest. 90*:626-630 (August, 1992).
	C77	Turunen, *et al.*, "Efficient adventitial gene delivery to rabbit carotid artery with cationic polymer - plasmic complexes, *Gene Therapy 6*:6-11 (1999).
✓	C78	Van Belle, *et al.*, "Passivation of metallic stents after arterial gene transfer of phVEGF$_{165}$ inhibits thrombus formation and intimal thickening," *J. Am. Coll. Cardiol. 29*:1371-1379 (May, 1997).

EXAMINER	E Hanley	DATE CONSIDERED	10-16-01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 28967/35061A	Serial No. 09/427,657
INFORMATION DISCLOSURE STATEMENT *(Use several sheets if necessary)*		Applicant Alitalo et al.	
		Filing Date Oct 26, 1999	Group 1633

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
	C79	Valtola, *et al.*, "VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer," *Am. J. Pathol. 154:*1381-1390 (May 1999).
	C80	Wang, *et al.*, "Signal transduction in human hematopoietic cells by vascular endothelial growth factor related protein, a novel ligand for the FLT4 receptor," *Blood 90(9)*:3507-15 (1997).
	C81	Wartiovaara, *et al.*, "Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation," *Thromb. Haemost. 80*:171-175 (1998).
	C82	Wilensky, *et al.*, "Methods and devices for local drug delivery in coronary and peripheral arteries," *Trends Cardiovasc. Med. 3*:163-170 (1993).
	C83	Willard, *et al.*, "Genetic modification of the vessel wall," *Circulation 89*:2190-2197 (1994).
	C84	Witzenbichler, *et al.*, "Bioactivity of vascular endothelial growth factor-2 (=VEGF-C) in vitro and in vivo following intraarterial administration of recombinant protein or intravascular gene transfer in a rabbit ischemic hindlimb model," *Eur Heart J. 18*:suppl. p.5 (1997).
	C85	Wolinsky, *et al.*, "Use of a perforated balloon catheter to deliver concentrated heparin into the wall of the normal canine artery," *J. Am. Coll. Cardiol. 15*:475-481 (February, 1990).
	C86	Ylä-Herttuala, *et al.*, "Biochemical composition of coronary arteries in Finnish children," *Arteriosclerosis 6*:230-236 (March/April, 1986).
	C87	Ylä-Herttuala, "Gene therapy for cardiovascular diseases," *Ann Med 28*:89-93 (1996).
	C88	Ylä-Herttuala, "Vascular gene transfer," *Curr Opin Lipidol* 8:72-76 (1997).

EXAMINER	DATE CONSIDERED 10-16-01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.